The CDC lowered the age for the pneumonia vaccination from 65 to 50 and recommended an extra COVID shot to some people.

Shares of the vaccine maker Moderna gained traction recently due to its updates of its vaccine trials with bang up results.

mRNA-1083 induced a higher antibody response ... Based on conservative projections, including revenue from the COVID-19 vaccine, RSV, seasonal flu, CMV, and melanoma (INT), Moderna's revenue ...

We recently compiled a list of the 10 Worst Performing Healthcare Stocks in 2024. In this article, we are going to take a ...

Nov. 18, 2024 — A new nasal whooping cough vaccine showed an ability to prevent both infection and transmission of the disease in mice. Current vaccines offer treatment but fail to halt ...

Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company specializing in messenger RNA (mRNA) therapeutics and vaccines. It develops synthetic mRNA that instructs cells to produce proteins to ...

It contains isolated proteins from the virus which help the immune system to fight it, but don’t contain any live pathogens (nor is it an mRNA vaccine). The Shingrix vaccine, given to prevent shingles ...

GSK has filed a pair of lawsuits against Moderna, claiming infringement of patents covering mRNA vaccines for COVID-19 and respiratory syncytial virus (RSV). According to court documents ...